PRISM® Platform - Wave Life Sciences
Our RNA medicines platform, PRISM ®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Wave Life Sciences
Nov 15, 2024 · Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
Wave Life Sciences Highlights Strategic Priorities and Expected …
Jan 13, 2025 · Wave’s RNA medicines platform, PRISM ®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with ...
Wave Life Sciences Announces Submission of First Clinical Trial ...
Dec 23, 2024 · Wave’s RNA medicines platform, PRISM ®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with ...
Wave Life Sciences Highlights Growing Pipeline at Research Day ...
Oct 30, 2024 · Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Wave Life Sciences Reports Second Quarter 2024 Financial Results …
Jun 30, 2024 · Wave’s RNA medicines platform, PRISM ®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with ...
Chandra Vargeese, PhD - Wave Life Sciences
In this role, she is responsible for the advancement of Wave’s PRISM™ platform, which combines best-in-class oligonucleotide chemistry, multiple RNA-targeting modalities, and novel insights from human genetics. PRISM is foundational to all of Wave’s drug discovery and development efforts.
Collaborations - Wave Life Sciences
Our collaboration with GSK aims to advance transformative oligonucleotide therapeutics, including WVE-006 for alpha-1 antitrypsin deficiency (AATD). The collaboration combines GSK’s unique insights from human genetics, as well as its global development and commercial capabilities, with Wave’s PRISM platform and oligonucleotide expertise.
Wave Life Sciences to Present at Upcoming Investor Conferences
Mar 27, 2024 · Wave’s RNA medicines platform, PRISM™, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Wave Life Sciences to Present at 2024 RBC Capital Markets Global ...
May 7, 2024 · Wave’s RNA medicines platform, PRISM™, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.